Kierkus Jaroslaw, Szymanska Edyta, Oracz Grzegorz, Wiernicka Anna, Dadalski Maciej
Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics.
Department of Pediatrics, Nutrition and Metabolic Disorders, The Children's Memorial Health Institute, Warsaw, Poland.
Pediatric Health Med Ther. 2015 Jun 11;6:79-85. doi: 10.2147/PHMT.S64943. eCollection 2015.
In recent years, a novel biologic therapy with monoclonal antibodies against tumor necrosis factor-alpha has revolutionized the treatment of Crohn's disease. Infliximab, the first biologic agent, has been demonstrated to considerably improve both clinical and endoscopic outcomes. In view of the growing popularity of infliximab in the management of Crohn's disease, we review the profile of the agent in the treatment of this disease in a pediatric setting.
近年来，一种针对肿瘤坏死因子-α的单克隆抗体新型生物疗法彻底改变了克罗恩病的治疗方式。首个生物制剂英夫利昔单抗已被证明能显著改善临床和内镜检查结果。鉴于英夫利昔单抗在克罗恩病治疗中的日益普及，我们综述了该制剂在儿科环境中治疗这种疾病的概况。
